When pharmaceutical teams investigate nitrosamine risk, attention often begins with the active pharmaceutical ingredient (API) and its manufacturing process. But the API is only part of the picture. Excipients can contribute to nitrosamine risk by introducing trace nitrite or other relevant precursors into a drug product. When those precursors encounter a susceptible amine under favorable formulation or storage conditions, nitrosamine formation may occur. This issue has become particularly important with the emergence of nitrosamine drug substance-related impurities (NDSRIs). Research has shown that nitrite levels can vary substantially among excipient types, grades, suppliers, and lots, and that excipient selection can materially affect predicted nitrosamine formation. More recent evidence suggests another layer of complexity: nitrite may not always be a completely static excipient attribute. Environmental exposure to nitrogen oxides (NOx) can increase nitrite levels in some excipients, with the extent depending on properties such as pH and surface area. For pharmaceutical development teams, this changes the central question from: “Does this excipient contain nitrite?” to: “How much nitrite could this excipient contribute, how variable is that contribution, and could it react with the API or another nitrosatable species under the conditions experienced by the drug product?” At topiox research, this mechanism-based approach can connect excipient assessment with formulation development, nitrosamine risk assessment, stability, confirmatory testing, and mitigation strategy.  

How Can Excipients Cause Nitrosamine Formation?

Excipients do not necessarily contain nitrosamines themselves. More commonly, they may contribute precursors or conditions that facilitate nitrosamine formation. A simplified mechanism is: Nitrite in excipient ↓ Nitrosating species under suitable conditions ↓ Nitrosatable amine in API, impurity, degradant, or other component ↓ N-nitrosation reaction ↓ Nitrosamine / NDSRI formation Therefore, three broad elements generally need to align:

1. A nitrosatable substrate
2. A source of nitrosating species
3. Conditions favorable for the reaction

The excipient may influence the second and third factors even when it is not itself the source of the amine. Reviews of pharmaceutical nitrosamine formation consistently identify interactions between amine-containing compounds and nitrosating species as important routes of nitrosamine formation in drug products.  

Why Nitrite in Excipients Matters

Trace nitrite is one of the most important excipient-related considerations in current nitrosamine risk assessment. Nitrite can be present at low levels in pharmaceutical excipients as a consequence of:

• raw-material origin;
• manufacturing processes;
• processing water;
• environmental exposure;
• storage;
• or other material-specific factors.

The amount may differ substantially among excipients. Even more importantly, the same nominal excipient can potentially show different nitrite levels depending on:

• grade;
• supplier;
• lot;
• manufacturing location;
• raw-material source;
• storage;
• and environmental history.

Research modeling common pharmaceutical formulations demonstrated that selecting lower-nitrite excipients or suppliers could substantially reduce predicted nitrosamine formation. This makes excipient nitrite more than a raw-material testing issue. It can become a formulation-development variable.  

Excipients Are Not Equally Important

An excipient containing measurable nitrite does not automatically represent the greatest nitrosamine risk. The total contribution depends on both: Nitrite concentration in the excipient and Amount of that excipient in the formulation Consider two hypothetical excipients.

Excipient A

Contains relatively high nitrite but is used at only 0.2% of the formulation.

Excipient B

Contains less nitrite per gram but represents 40% of the tablet. Excipient B could potentially contribute more total nitrite to the dosage form. Therefore: Excipient nitrite risk ≠ nitrite concentration alone A more useful assessment considers: Nitrite level × Excipient amount × Product dose × Nitrosation potential This is particularly relevant for high-load excipients such as fillers and diluents.  

Which Excipients Can Contribute Nitrite?

Nitrite has been detected at varying levels across many pharmaceutical excipient categories. Potentially relevant materials can include, depending on grade and source:

• microcrystalline cellulose;
• lactose;
• starches;
• povidone;
• crospovidone;
• croscarmellose sodium;
• sodium starch glycolate;
• magnesium stearate;
• inorganic excipients;
• and other commonly used pharmaceutical materials.

This list should not be interpreted as meaning these excipients are inherently unsafe or automatically high-risk. The actual concern depends on:

• measured nitrite;
• formulation loading;
• API susceptibility;
• manufacturing conditions;
• storage conditions;
• and total product exposure.

For example, research modeling microcrystalline cellulose, lactose, and superdisintegrant selection showed that differences among excipient sources could materially alter theoretical nitrosamine formation. The appropriate question is therefore not: “Is microcrystalline cellulose a nitrosamine risk?” It is: “What is the nitrite contribution of this specific material in this specific formulation?”  

Excipient Nitrite Levels Can Vary Between Suppliers

Supplier variability is particularly important. Two excipients that meet the same pharmacopoeial identity and conventional quality specifications can potentially contain different trace levels of nitrite. This means conventional excipient specifications may not always provide enough information for nitrosamine risk assessment. Berardi and colleagues modeled the effect of changing excipient suppliers and found that changing the supplier of a single excipient could reduce predicted nitrosamine formation substantially, while optimizing several critical excipients produced even larger reductions in the modeled formulations. This creates an important development principle: Supplier selection can become part of the nitrosamine control strategy.  

Excipient Nitrite May Not Be a Completely Static Attribute

One of the more important recent scientific findings is that nitrite levels in excipients may change after manufacture. A 2026 investigation exposed a broad range of common excipients to nitrogen oxides and observed nitrite accumulation in many materials. The extent depended partly on physicochemical properties such as:

• pH;
• specific surface area;
• and excipient chemistry.

The researchers also observed increased nitrite after ambient-air exposure under laboratory conditions. This suggests that nitrite risk assessment may need to consider not only the excipient’s initial specification but also: manufacturing environment → handling → storage → environmental exposure The practical implications are still developing, and the significance under specific commercial manufacturing conditions should be established rather than assumed. However, the findings reinforce an important point: A single historical nitrite value may not fully describe every future lot or use condition.  

API Structure Determines Whether Nitrite Becomes a Nitrosamine Risk

Nitrite alone does not automatically produce a nitrosamine. A nitrosatable amine or related precursor must also be available. This can come from:

• the API;
• an API degradant;
• an API impurity;
• a process impurity;
• another formulation component;
• or another relevant source.

Secondary amines are particularly relevant to nitrosation chemistry, although actual susceptibility depends on molecular structure and reaction conditions. For NDSRIs, the nitrosatable group may be part of the drug substance itself. Research has demonstrated direct formation of NDSRIs from secondary-amine-containing APIs under nitrosating conditions, with susceptibility differing significantly among molecular structures. The risk equation therefore becomes: Excipient nitrite + susceptible API/amine + favorable conditions = potential NDSRI formation  

Formulation pH Can Influence Nitrosamine Formation

The presence of nitrite and an amine does not guarantee rapid nitrosamine formation. Reaction conditions matter. One particularly important factor is pH. Nitrite chemistry is strongly affected by the local acid-base environment. Under appropriate acidic conditions, nitrite can generate nitrosating species capable of reacting with susceptible amines. This means formulation pH—or even local microenvironmental pH around particles—may influence nitrosamine formation. Importantly, bulk product pH may not always fully represent the microenvironment in a heterogeneous solid dosage form. The scientific question should therefore be: Do the formulation conditions permit meaningful nitrosation over manufacturing and shelf life? rather than: Does the product contain nitrite? Recent research also illustrates this complexity. Carbonate excipients were observed to accumulate relatively high absolute nitrite levels after NOx exposure, but their basic pH could simultaneously create a less favorable environment for nitrosamine formation. Therefore: Higher nitrite does not always translate directly into proportionally higher nitrosamine formation.  

Moisture Can Influence the Reaction Environment

Water can influence molecular mobility and chemical reaction pathways within a drug product. In solid dosage forms, moisture may affect:

• dissolution of trace nitrite;
• mobility of reactive species;
• local pH;
• API–excipient interactions;
• degradation;
• and nitrosation kinetics.

Consequently, moisture content and water activity may become relevant during nitrosamine root-cause investigations. This is also why storage conditions can matter. A formulation that shows little nitrosamine formation initially may behave differently after prolonged exposure to:

• elevated humidity;
• elevated temperature;
• or other stability conditions.

Nitrosamine risk assessment should therefore connect excipient chemistry with stability behavior rather than treating formulation composition as static.  

Manufacturing Process Can Change Excipient-Related Risk

Two formulations containing identical ingredients may not necessarily produce identical nitrosamine profiles. Manufacturing conditions can change the extent to which precursors interact. Relevant variables may include:

• wet granulation;
• dry granulation;
• direct compression;
• fluid-bed processing;
• coating;
• drying temperature;
• drying time;
• hold times;
• water addition;
• mixing;
• and environmental exposure.

Wet processing can be particularly important because increased molecular mobility may facilitate reactions between nitrite and nitrosatable compounds. Berardi and colleagues specifically incorporated conversion rates associated with formulation and manufacturing conditions into their nitrosamine-formation modeling and highlighted higher-risk scenarios such as wet granulation. Recent findings concerning NOx-driven nitrite accumulation also raise scientific questions about manufacturing operations involving substantial air throughput, such as fluid-bed processing and coating. These mechanisms require product-specific evaluation.  

Why Shelf Life Matters

Nitrosamine formation can continue after manufacturing. During storage, the API and excipients remain in prolonged contact. Over months or years:

• nitrite can interact with susceptible amines;
• APIs can degrade;
• new amine-containing degradants can form;
• moisture can change;
• microenvironments can evolve;
• and reaction products can accumulate.

This creates an important distinction: Initial nitrosamine level ≠ maximum shelf-life nitrosamine level A recent pharmaceutical case study demonstrated why nitrosamine monitoring through shelf life can be important even when most targeted impurities remain absent or below relevant limits. For excipient-related risk, stability studies can therefore help determine whether a theoretical precursor combination actually produces increasing nitrosamine levels over time.  

A Practical Excipient Nitrosamine Risk Framework

A useful assessment can follow this sequence:

1. Identify nitrosatable API structures and relevant degradants ↓ 2. Identify nitrite-containing excipients ↓ 3. Determine excipient loading in the formulation ↓ 4. Evaluate supplier and lot variability ↓ 5. Estimate total nitrite contribution per dosage unit ↓ 6. Assess formulation pH and microenvironment ↓ 7. Evaluate manufacturing conditions ↓ 8. Consider moisture and storage conditions ↓ 9. Identify plausible NDSRIs or other nitrosamines ↓ 10. Conduct confirmatory testing where scientifically warranted ↓ 11. Establish mitigation and lifecycle controls

This framework helps distinguish theoretical precursor presence from a scientifically plausible product risk.  

How Should Excipient Nitrite Contribution Be Evaluated?

A practical starting concept is: Nitrite contribution per excipient = Nitrite concentration × Amount of excipient in the drug product Total formulation nitrite contribution can then be estimated across relevant excipients. But that value alone does not predict the final nitrosamine concentration. Additional factors include:

• nitrosatable amine availability;
• reaction stoichiometry;
• percentage conversion;
• pH;
• moisture;
• temperature;
• manufacturing process;
• storage duration;
• and molecular characteristics of the API.

Berardi and colleagues demonstrated how formulation composition, excipient nitrite levels, nitrosamine molecular weight, and assumed conversion can be integrated to estimate theoretical nitrosamine formation. Such calculations can be useful for risk ranking, but they should not be mistaken for direct measurement of actual nitrosamine formation.  

Can Changing Excipient Suppliers Reduce Nitrosamine Risk?

Potentially, yes. If an excipient makes a major contribution to total formulation nitrite, selecting a material with consistently lower nitrite may reduce precursor availability. In theoretical case studies, changing the supplier of one critical excipient reduced predicted nitrosamine formation by up to approximately 59%, while optimizing three important excipients produced reductions of up to approximately 89%. These values came from modeled scenarios and should not be interpreted as universal reductions achievable in every formulation. However, they demonstrate the potential value of excipient selection as a mitigation tool. A supplier change should also consider:

• pharmaceutical functionality;
• material variability;
• dissolution;
• manufacturability;
• stability;
• bioavailability;
• regulatory impact;
• and other critical quality attributes.

Nitrosamine mitigation should not create a new product-quality problem.  

Can Nitrite Scavengers Reduce Nitrosamine Formation?

Another potential mitigation approach is the use of nitrite scavengers. Compounds investigated include:

• ascorbic acid;
• sodium ascorbate;
• α-tocopherol;
• amino acids;
• cysteine;
• propyl gallate;
• and other antioxidants or reactive compounds.

A review of nitrosamine mitigation in oral drug products describes ascorbic acid and other scavengers as potential strategies for reducing nitrosamine formation. Experimental research evaluating multiple scavengers found several capable of reducing nitrosation under studied conditions, including vitamin C, PABA, and L-cysteine. However: Nitrite scavenging activity does not automatically equal complete inhibition of nitrosamine formation. The effectiveness depends on:

• formulation;
• API;
• reaction mechanism;
• scavenger concentration;
• physical state;
• pH;
• and storage conditions.

Adding a scavenger can also affect product quality and may constitute a formulation change requiring appropriate pharmaceutical and regulatory evaluation.  

Excipient Selection vs Nitrite Scavengers

These strategies address the problem differently.

Lower-Nitrite Excipient Selection

Reduces the amount of precursor entering the formulation.

Nitrite Scavenger Strategy

Attempts to consume or intercept nitrite before it reacts with the nitrosatable substrate. Where feasible, reducing precursor input can be a particularly direct risk-reduction strategy. However, the most appropriate solution depends on the formulation. A useful development hierarchy can be: Understand the mechanism ↓ Reduce precursor sources where practical ↓ Optimize formulation/process conditions ↓ Evaluate additional mitigation strategies where needed ↓ Confirm effectiveness analytically ↓ Monitor through shelf life  

Analytical Testing for Excipient-Related Nitrosamine Risk

Analytical testing may occur at several levels.

Nitrite Testing of Excipients

This helps identify materials or suppliers contributing significant precursor levels.

Amine/Precursor Testing

Relevant amine impurities or degradants may also need investigation.

Nitrosamine Confirmatory Testing

Where a plausible risk is identified, sensitive analysis may be required for the specific nitrosamine or NDSRI. Common analytical platforms include:

• LC-MS/MS;
• LC-HRMS;
• GC-MS;
• and GC-MS/MS,

depending on the target impurity. Nitrosamine analysis frequently requires trace-level sensitivity and high selectivity because of the very low concentrations involved. Testing should follow the risk assessment. It should answer specific questions rather than becoming an indiscriminate analytical screen.  

Avoiding Nitrosamine Formation During Sample Preparation

A particularly important analytical issue is artifactual nitrosamine formation. If a sample contains both nitrite and a nitrosatable amine, the analytical preparation itself can potentially create conditions that promote nitrosation. This can produce an apparent nitrosamine result that does not accurately represent the original drug product. Research has even demonstrated trace nitrosamine formation inside an LC-MS analytical system when an amine and nitrite were combined under particular conditions. For excipient-related investigations, sample preparation should therefore be evaluated carefully for:

• pH;
• extraction solvent;
• extraction time;
• temperature;
• nitrite availability;
• and sample stability.

A highly sensitive method is useful only if it measures the impurity that was actually present in the product.  

Regulatory Context for Excipient-Related Nitrosamine Risk

Current regulatory frameworks recognize that nitrosamine formation can occur in the finished drug product, including through interactions between nitrite-containing excipients and nitrosatable APIs or related compounds. For pharmaceutical development teams, the regulatory strategy should integrate: Risk assessment ↓ Identification of plausible formation pathways ↓ Confirmatory testing where risk is identified ↓ Comparison with the applicable acceptable intake ↓ Root-cause investigation ↓ Mitigation and control Acceptable intake limits are nitrosamine-specific and may be established using compound-specific data, read-across, structural approaches such as the Carcinogenic Potency Categorisation Approach (CPCA), or other regulator-supported evidence. Because acceptable intake information and nitrosamine science continue to evolve, current regulatory resources should be checked for the specific impurity rather than relying on historical limits.  

Common Mistakes in Excipient Nitrosamine Risk Assessment

Assuming All Lots Have the Same Nitrite Level

Excipient nitrite can vary by supplier, lot, material history, and potentially environmental exposure.

Looking Only at Nitrite Concentration

Formulation loading also matters.

Assuming Nitrite Automatically Means Nitrosamine Formation

A susceptible amine and appropriate reaction conditions are also required.

Ignoring pH

Nitrosation chemistry can be strongly dependent on the local chemical environment.

Ignoring Manufacturing Conditions

Wet processing, temperature, air exposure, and hold times may alter precursor interaction.

Ignoring Shelf Life

Nitrosamine formation can continue during storage.

Assuming Supplier Certificates Answer Every Question

Conventional excipient specifications may not fully characterize trace nitrite variability relevant to a particular nitrosamine risk assessment.

Changing an Excipient Without Considering Product Performance

Excipient selection affects much more than nitrite.

Treating Scavengers as a Universal Solution

Mitigation effectiveness is formulation- and mechanism-specific.

Testing Without Understanding the Formation Pathway

Sensitive analysis is most valuable when it addresses a clearly defined scientific risk.  

Best Practices for Managing Excipient-Related Nitrosamine Risk

Identify Nitrosatable Structures Early

Review the API, impurities, and degradants during development.

Build an Excipient Nitrite Map

Understand which excipients contribute the greatest theoretical nitrite load.

Consider Both Concentration and Formulation Loading

High-use excipients can matter even at relatively modest nitrite concentrations.

Characterize Supplier Variability

Where risk warrants it, evaluate multiple suppliers or lots.

Understand Formulation Conditions

Consider pH, moisture, physical state, and component proximity.

Evaluate Manufacturing Risk

Assess whether processing increases mobility or creates conditions favorable to nitrosation.

Include Stability in the Assessment

Determine whether nitrosamines increase during shelf life.

Reduce Precursors Where Practical

Lower-nitrite excipients may provide a direct mitigation route.

Evaluate Scavengers Scientifically

Confirm compatibility, effectiveness, and stability rather than assuming benefit.

Verify Mitigation Analytically

Demonstrate that the proposed strategy actually reduces the relevant nitrosamine or NDSRI.

Maintain Lifecycle Controls

Supplier, process, formulation, or storage changes may justify reassessment.  

Excipient Risk Assessment at topiox research

Excipient-related nitrosamine risk sits at the intersection of:

• formulation development;
• excipient characterization;
• nitrite analysis;
• API and degradant chemistry;
• NDSRI assessment;
• stability;
• LC-MS/MS and GC-MS analysis;
• root-cause investigation;
• and regulatory strategy.

At topiox research, excipient-focused nitrosamine assessment can be integrated into broader pharmaceutical development programs to help determine:

• which excipients contribute nitrite;
• whether the API is susceptible to nitrosation;
• how formulation and process conditions affect risk;
• whether NDSRIs could form during shelf life;
• when confirmatory testing is warranted;
• and which mitigation strategies are scientifically appropriate.

The objective is not simply to classify an excipient as: “high nitrite” or “low nitrite.” The more useful question is: “How does this excipient contribute to the complete nitrosamine formation pathway in this specific drug product?”

Conclusion

Excipients can play an important role in pharmaceutical nitrosamine risk, particularly when they introduce trace nitrite into formulations containing nitrosatable APIs or related compounds. But nitrite concentration alone does not determine risk. A meaningful assessment should consider:

1. API and degradant structure
2. Nitrite concentration in excipients
3. Excipient loading
4. Supplier and lot variability
5. Formulation pH and microenvironment
6. Moisture
7. Manufacturing conditions
8. Environmental exposure
9. Shelf-life formation
10. Potential NDSRIs
11. Applicable acceptable intake
12. Mitigation and lifecycle control

The key scientific relationship is: Excipient nitrite + nitrosatable amine + favorable reaction environment + time → potential nitrosamine formation Research shows that excipient selection can substantially alter theoretical nitrosamine formation, while newer evidence indicates that environmental exposure can also influence nitrite levels in some excipients. At topiox research, integrating excipient assessment with formulation science, stability, NDSRI evaluation, trace analysis, and root-cause investigation can help development teams move beyond simple nitrite screening toward a mechanistic nitrosamine control strategy. Evaluating excipient-related nitrosamine risk in a drug product? Connect with topiox research for excipient nitrite assessment, NDSRI risk evaluation, confirmatory nitrosamine analysis, stability investigations, and formulation-focused root-cause and mitigation support.